Skip to main content
    • Aa
    • Aa
  • The International Journal of Neuropsychopharmacology, Volume 16, Issue 2
  • March 2013, pp. 313-321

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder*

  • Rakesh Jain (a1) (a2), Atul R. Mahableshwarkar (a3), Paula L. Jacobsen (a3), Yinzhong Chen (a3) and Michael E. Thase (a4)
  • DOI:
  • Published online: 11 September 2012

Vortioxetine (Lu AA21004) is a multi-modal antidepressant in clinical development for the treatment of major depressive disorder (MDD). The current study evaluated the efficacy and tolerability of 5 mg vortioxetine compared to placebo after 6 wk of treatment in adults with MDD in an out-patient setting. Adults aged 18–75 yr, with a diagnosis of MDD and a baseline Montgomery–Asberg Depression Rating Scale (MADRS) total score ⩾30, were randomized to receive either 5 mg vortioxetine or placebo over 6 wk, followed by a 2-wk medication-free discontinuation period. The primary efficacy measure was change from baseline in Hamilton Rating Scale for Depression (HAMD)-24 total score at week 6 compared to placebo. Additional measures included response and remission rates, Clinical Global Impression Scale – Improvement scores, HAMD-24 total score in subjects with baseline Hamilton Anxiety Scale (HAMA) >19 and MADRS-S total score. Adverse events (AEs) were assessed throughout the study. A total of 600 adults were randomized. There were no significant differences in efficacy measures between subjects in the 5 mg vortioxetine and placebo groups at week 6. HAMD-24 total score in subjects with baseline HAMA >19 in the 5 mg vortioxetine group was improved at weeks 3–6 compared to the placebo group (nominal p value <0.05). The most common AEs for the vortioxetine and placebo groups were nausea (19.1 and 9.4%), headache (17.1 and 15.1%) and diarrhoea (11.4 and 7.0%), respectively. In this study of adults with MDD, 5 mg vortioxetine did not differ significantly from placebo in reducing depression symptoms after 6 wk of treatment.

Corresponding author
Address for correspondence: M. E. Thase, MD, Department of Psychiatry, Mood and Anxiety Disorders Treatment and Research Program, University of Pennsylvania, 3535 Market Street, Suite 670, Philadelphia, PA 19104-3309, USA. Tel.: 215 746 6680 Fax: 215 573 0759Email:
Hide All

This trial has been registered at #NCT00672958.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

E Alvarez , V Perez , M Dragheim , H Loft , (2011). A double-blind, randomized, placebo-controlled, active reference study of vortioxetine in patients with major depressive disorder. International Journal of Neuropsychopharmacology 15, 589600.

AK Ashton , BD Jamerson , W Weinstein , C Wagoner (2005). Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Current Therapeutic Research 66, 96106.

B Bang-Andersen , T Ruhland , M Jorgensen , G Smith , (2011). Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (vortioxetine): a novel multimodal compound for the treatment of major depressive disorder. Journal of Medicinal Chemistry 54, 32063221.

JP Boulenger , H Loft , I Florea (2012). A randomized clinical study of vortioxetine in the prevention of relapse in patients with major depressive disorder. Journal of Psychopharmacology. Published online: 9 April 2012. doi:10.1177/0269881112441866.

JA Bridge , B Birmaher , S Iyengar , RP Barbe , (2009). Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. American Journal of Psychiatry 166, 4249.

AR Brunoni , M Lopes , TJ Kaptchuk , F Fregni (2009). Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS ONE 4, e4824.

RA Hansen , G Gartlehner , KN Lohr , BN Gaynes , (2005). Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine 143, 415426.

DS Hasin , RD Goodwin , FS Stinson , BF Grant (2005). Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Archives of General Psychiatry 62, 10971106.

N Henigsberg , A Mahableshwarkar , P Jacobsen , Y Chen , (2011). P.2.c.018 Efficacy and tolerability of multiple doses of LU AA21004 in an 8-week trial of adults with major depressive disorder. European Neuropsychopharmacology 21 (Suppl. 3), S393.

XH Hu , SA Bull , EM Hunkeler , E Ming , (2004). Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report vs. physician estimate. Journal of Clinical Psychiatry 65, 959965.

LL Judd , HS Akiskal , PJ Zeller , M Paulus , (2000). Psychosocial disability during the long-term course of unipolar major depressive disorder. Archives of General Psychiatry 57, 375380.

W Katon , P Ciechanowski (2002). Impact of major depression on chronic medical illness. Journal of Psychosomatic Research 53, 859863.

C Katona , T Hansen , CK Olsen . (2012). A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of vortioxetine in elderly patients with major depressive disorder. International Clinical Psychopharmacology 27, 215223.

RC Kessler , P Berglund , O Demler , R Jin , (2003). The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). Journal of the American Medical Association 289, 30953105.

A Khan , A Bhat , R Kolts , ME Thase , (2010). Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neuroscience and Therapeutics 16, 217226.

CH Mallinckrodt , RN Tamura , Y Tanaka (2011). Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. Journal of Psychiatric Research 45, 12021207.

A Mork , A Pehrson , L Tottrup Brennum , S Moller Nielsen , (2011). Pharmacological effects of vortioxetine: a novel multimodal compound for the treatment of major depressive disorder. Journal of Pharmacology and Experimental Therapeutics 340, 666675.

JC Mundt , JH Greist , JW Jefferson , DJ Katzelnick , (2007). Is it easier to find what you are looking for if you think you know what it looks like? Journal of Clinical Psychopharmacology 27, 121125.

S Rosenzweig-Lipson , CE Beyer , ZA Hughes , X Khawaja , (2007). Differentiating antidepressants of the future: efficacy and safety. Pharmacology and Therapeutics 113, 134153.

LE Schechter , RH Ring , CE Beyer , ZA Hughes , (2005). Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRX 2, 590611.

S Stewart-Williams , J Podd (2004). The placebo effect: dissolving the expectancy vs. conditioning debate. Psychology Bulletin 130, 324340.

D Warden , A Rush , M Trivedi , M Fava , (2007). The STAR*D project results: a comprehensive review of findings. Current Psychiatry Reports 9, 449459.

C Zlotnick , R Kohn , G Keitner , SA Della Grotta (2000). The relationship between quality of interpersonal relationships and major depressive disorder: findings from the National Comorbidity Survey. Journal of Affective Disorders 59, 205215.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *